PMID- 33287663
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20220308
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse 
      Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric 
      ALL Patients.
PG  - 1533033820980113
LID - 10.1177/1533033820980113 [doi]
LID - 1533033820980113
AB  - OBJECTIVE: This study aimed to investigate the correlation of L-asparaginase 
      (L-asp) activity, anti-L-asp antibody, asparagine and glutamine levels with the 
      risks of adverse events (AEs), especially anaphylaxis, in pediatric acute 
      lymphoblastic leukemia (ALL) patients who underwent polyethylene 
      glycol-conjugated L-asp (PEG-asp)-contained treatment. METHODS: Plasma samples 
      were collected from 91 pediatric ALL patients who underwent PEG-asp-contained 
      treatment on the 7th day after drug administration. Plasma L-asp activity, 
      anti-L-asp antibody level, asparagine level and glutamine level were detected. 
      Meanwhile, AEs related to PEG-asp administration were recorded. RESULTS: AEs 
      occurred in 13 (14.3%) patients, among which 7 (7.7%) patients had anaphylaxis, 
      while another 6 patients had non-anaphylaxis AEs (including 4 (4.4%) patients who 
      had acute pancreatitis, 1 (1.1%) patient who had abdominal pain and diarrhea, as 
      well as 1 (1.1%) patient who had nausea and vomiting). L-asp activity was 
      decreased, while asparagine and glutamine levels were increased in patients with 
      AEs compared to patients without AEs, and ROC curves showed that they were 
      correlated with higher AEs risk. Notably, further analyses revealed that L-asp 
      activity, anti-L-asp antibody, asparagine and glutamine levels were highly 
      correlated with anaphylaxis risk, but they were not associated with the risk of 
      non-anaphylactic AEs. CONCLUSION: The measurement of L-asp activity, anti-L-asp 
      antibody level, asparagine level and glutamine level might assist the prevention 
      of anaphylaxis-related AEs in pediatric ALL patients who underwent 
      PEG-asp-contained treatment.
FAU - Wu, Juan
AU  - Wu J
AD  - Department of Pharmacy, Shanghai Children's Medical Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
FAU - Chen, Changcheng
AU  - Chen C
AD  - Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
FAU - Huang, Shiying
AU  - Huang S
AD  - Department of Pharmacy, Shanghai Children's Medical Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
FAU - Shen, Shuhong
AU  - Shen S
AD  - Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
FAU - Zhang, Shunguo
AU  - Zhang S
AUID- ORCID: 0000-0003-0891-7123
AD  - Department of Pharmacy, Shanghai Children's Medical Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers)
RN  - 0RH81L854J (Glutamine)
RN  - 7006-34-0 (Asparagine)
RN  - EC 3.5.1.1 (Asparaginase)
SB  - IM
CIN - Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211049902. PMID: 34738840
CIN - Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211049894. PMID: 34738842
MH  - Adolescent
MH  - Age Factors
MH  - Anaphylaxis/*blood/diagnosis/*etiology
MH  - Antineoplastic Agents, Immunological/administration & dosage/adverse 
      effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Asparaginase/antagonists & inhibitors/*blood
MH  - Asparagine/blood
MH  - Biomarkers/blood
MH  - Child
MH  - Child, Preschool
MH  - Drug Hypersensitivity/*blood/diagnosis/*etiology
MH  - Female
MH  - Glutamine/blood
MH  - Humans
MH  - Infant
MH  - Male
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*complications/drug therapy
MH  - Prognosis
MH  - ROC Curve
PMC - PMC7727045
OTO - NOTNLM
OT  - L-asparaginase activity
OT  - adverse events
OT  - anaphylaxis
OT  - pediatric acute lymphoblastic leukemia
OT  - polyethylene glycol-conjugated L-asparaginase
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/12/09 06:00
MHDA- 2021/11/23 06:00
PMCR- 2020/12/08
CRDT- 2020/12/08 05:30
PHST- 2020/12/08 05:30 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PHST- 2020/12/08 00:00 [pmc-release]
AID - 10.1177_1533033820980113 [pii]
AID - 10.1177/1533033820980113 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980113. doi: 
      10.1177/1533033820980113.